Compare IDN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | INKT |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 70.6M |
| IPO Year | 2014 | 2021 |
| Metric | IDN | INKT |
|---|---|---|
| Price | $4.16 | $11.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.33 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 393.7K | 22.5K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $138.00 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $3.95 | $7.01 |
| 52 Week High | $9.08 | $76.00 |
| Indicator | IDN | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 48.82 |
| Support Level | $3.99 | $10.82 |
| Resistance Level | $5.07 | $12.61 |
| Average True Range (ATR) | 0.19 | 0.66 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 33.33 | 35.19 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.